Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer

被引：39

作者：

Morales, M

Santana, N

Soria, A

Mosquera, A

Ordovas, J

Novoa, J

Betancor, P

Valeron, PF

DiazChico, B

Chirino, R

机构：

[1] UNIV PALMAS GC,CTR CIENCIAS SALUD,DPTO ENDOCRINOL C&M,LAS PALMAS 35080,SPAIN

[2] HOSP NUESTRA SENORA CANDELARIA,DIV MED ONCOL,TENERIFE,SPAIN

[3] HOSP INSULAR,DEPT CLIN CHEM,LAS PALMAS,SPAIN

[4] TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,BOSTON,MA 02111

[5] UNIV LAS PALMAS GC,DEPT CLIN SCI,LAS PALMAS,SPAIN

来源：

BREAST CANCER RESEARCH AND TREATMENT | 1996年 / 40卷 / 03期

关键词：

apolipoproteins; breast cancer; cardiovascular disease; lipoproteins; lipoprotein(a); tamoxifen;

D O I：

10.1007/BF01806815

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Serum lipids and apolipoprotein levels were measured in twenty postmenopausal women with primary breast cancer, before and three months after tamoxifen therapy (10 mg twice a day). Tamoxifen caused a significant reduction in total serum cholesterol (10%; P < 0.02), and in low-density lipoprotein cholesterol (17%: P < 0.01), and a significant 47% increase in the subclass 2 of the high density lipoprotein cholesterol (P < 0.01). In addition, tamoxifen caused a 16% increase in apolipoprotein A-I, a 12% decrease in apolipoprotein B (P < 0.05), and a 37% reduction in the serum concentration of lipoprotein(a) (P < 0.01). These results show that tamoxifen brings about an important improvement in serum lipid profile.

引用

页码：265 / 270

页数：6

共 33 条

[1] REDUCTION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE, APOLIPOPROTEIN D AND THE LP(A) LIPOPROTEIN WITH THE ANABOLIC-STEROID STANOZOLOL [J].